• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Aemcolo (rifamycin)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Aemcolo (rifamycin)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Aemcolo (rifamycin) is an antibacterial drug.

    Aemcolo is specifically indicated for the treatment of travelers’ diarrhea caused by noninvasive strains of Escherichia coli in adults.

    Aemcolo is supplied as a delayed-release tablet for oral administration. The recommended dose is 388 mg (two tablets) orally twice daily for three days. Take each dose with a glass of liquid. Do not take Aemcolo concomitantly with alcohol. Aemcolo can be taken with or without food. Tablets should be swallowed whole. Do not crush, break or chew the tablets. 

    Clinical Results

    FDA Approval

    The FDA approval of Aemcolo was based on  data from two randomized, multi-center, controlled Phase III clinical trials. Trial 1 was conducted at clinical sites in Guatemala and Mexico, and provided the primary evidence for the efficacy of Aemcolo. A second active-controlled trial (Trial 2) was conducted in India, Guatemala and Ecuador, and provided supportive evidence. In both trials Aemcolo was dosed at 388mg twice daily for three days. Aemcolo demonstrated superiority to placebo and non-inferiority to ciprofloxacin for the primary endpoint (time to last unformed stool).

    Side Effects

    Adverse effects associated with the use of Aemcolo may include, but are not limited to, the following:

    headache

    constipation

    Mechanism of Action

    Aemcolo (rifamycin) belongs to the ansamycin class of antibacterial drugs and acts by inhibiting the beta subunit of the bacterial DNA-dependent RNA polymerase, blocking one of the steps in DNA transcription. This results in inhibition of bacterial synthesis and consequently growth of bacteria.

    Additional Information

    For additional information regarding Aemcolo or traveler's diarrhea, please visit https://www.ariespharma.com/

    Approval Date: 2018-11-01
    Company Name: Aries Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing